Showing results (1931-1940 of 2,013) with videos related to
Sort By:
Pageof 202
Scientific Reports|April 29, 2026
Unraveling the physiological impact of ANGPTL8 loss-of-function variants in humansArkan Abadi, Yan Q Chen, Shareef Khalid, et al.Carcinogenesis|June 25, 2015
Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?R Brooks Robey, Judith Weisz, Nancy B Kuemmerle, et al.Carcinogenesis|June 25, 2015
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signallingWilhelm Engström, Philippa Darbre, Staffan Eriksson, et al.Carcinogenesis|June 25, 2015
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesisZhiwei Hu, Samira A Brooks, Valérian Dormoy, et al.Proceedings of the National Academy of Sciences of the United States of America|December 18, 2019
Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinomaRebecca L Porter, Neelima K C Magnus, Vishal Thapar, et al.American Journal of Human Genetics|May 29, 2003
Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics InitiativeDanielle M Dick, Tatiana Foroud, Leah Flury, et al.Cancer Discovery|December 31, 2016
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive CholangiocarcinomaLipika Goyal, Supriya K Saha, Leah Y Liu, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2012
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelinesAl B Benson, J Pablo Arnoletti, Tanios Bekaii-Saab, et al.Seminars in Cancer Biology|March 31, 2015
Immune evasion in cancer: Mechanistic basis and therapeutic strategiesDass S Vinay, Elizabeth P Ryan, Graham Pawelec, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2014
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaDarrell R Borger, Lipika Goyal, Thomas Yau, et al.Pageof 202